Business Description
Equillium Inc
NAICS : 325412
SIC : 2834
ISIN : US29446K1060
Description
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 49.6 | |||||
| Equity-to-Asset | 0.45 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -3.45 | |||||
| Beneish M-Score | -0.82 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 37.1 | |||||
| 3-Year EPS without NRI Growth Rate | 36.2 | |||||
| 3-Year FCF Growth Rate | 19.8 | |||||
| 3-Year Book Growth Rate | -39 | |||||
| Future 3-5Y Total Revenue Growth Rate | -4.53 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.56 | |||||
| 9-Day RSI | 36.6 | |||||
| 14-Day RSI | 38.65 | |||||
| 6-1 Month Momentum % | 316.94 | |||||
| 12-1 Month Momentum % | 263.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.79 | |||||
| Quick Ratio | 1.79 | |||||
| Cash Ratio | 1.48 | |||||
| Days Sales Outstanding | 35.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.5 | |||||
| Shareholder Yield % | 14.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -40.25 | |||||
| Net Margin % | -36.96 | |||||
| FCF Margin % | -60.31 | |||||
| ROE % | -49.44 | |||||
| ROA % | -21.18 | |||||
| ROIC % | -79.12 | |||||
| ROC (Joel Greenblatt) % | -912.09 | |||||
| ROCE % | -36.14 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 3.04 | |||||
| PS Ratio | 1.61 | |||||
| PB Ratio | 2.61 | |||||
| Price-to-Tangible-Book | 2.62 | |||||
| EV-to-EBIT | -1.54 | |||||
| EV-to-EBITDA | -1.55 | |||||
| EV-to-Revenue | 0.52 | |||||
| EV-to-Forward-Revenue | 0.27 | |||||
| EV-to-FCF | -0.86 | |||||
| Price-to-Net-Current-Asset-Value | 2.73 | |||||
| Price-to-Net-Cash | 4.48 | |||||
| Earnings Yield (Greenblatt) % | -64.94 | |||||
| FCF Yield % | -37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Equillium Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 33.471 | ||
| EPS (TTM) (€) | -0.362 | ||
| Beta | 0.22 | ||
| Volatility % | 216.03 | ||
| 14-Day RSI | 38.65 | ||
| 14-Day ATR (€) | 0.106661 | ||
| 20-Day SMA (€) | 1.6105 | ||
| 12-1 Month Momentum % | 263.64 | ||
| 52-Week Range (€) | 0.4205 - 2.66 | ||
| Shares Outstanding (Mil) | 35.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Equillium Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Equillium Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Equillium Inc Frequently Asked Questions
What is Equillium Inc(STU:0FY)'s stock price today?
The current price of STU:0FY is €1.39. The 52 week high of STU:0FY is €2.66 and 52 week low is €0.42.
When is next earnings date of Equillium Inc(STU:0FY)?
The next earnings date of Equillium Inc(STU:0FY) is 2024-05-10 Est..
Does Equillium Inc(STU:0FY) pay dividends? If so, how much?
Equillium Inc(STU:0FY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers